CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling [Seeking Alpha]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Seeking Alpha
However, I believe the other candidate I noted above, CX-2051, is even more important for pipeline expansion. Why is that? That's because it is said that up to 70% of these solid tumor types carry the EpCAM expression. Lastly, there is another drug in its pipeline that may have added potential. This would be regarding the use of CX-801 which is being advanced for solid tumor types like: Head and neck squamous cell carcinoma, melanoma and renal cancer [kidney cancer]. Initiation of a phase 1 study, using this drug for the treatment of this patient population, is expected in the 1st half of 2024. With the upcoming release of data from the phase 1a dose-escalation study using CX-904 for the treatment of EGFR-expressing solid tumors, plus the advancement of an ADC and cytokine utilizing its Probody therapeutics technology platform, I believe that CytomX Therapeutics, Inc. investors can benefit with any potential gains made. Editor's Note: This article discusses one or more securities
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics Announces New Employment Inducement GrantsGlobeNewswire
- CytomX Therapeutics, Inc. (NASDAQ: CTMX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its price target raised by analysts at BMO Capital Markets from $3.25 to $3.59. They now have a "market perform" rating on the stock.MarketBeat
CTMX
Earnings
- 5/8/24 - Miss
CTMX
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- CTMX's page on the SEC website